These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 17020536)

  • 41. Novel reactions catalysed by antibodies.
    Golinelli-Pimpaneau B
    Curr Opin Struct Biol; 2000 Dec; 10(6):697-708. PubMed ID: 11114507
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Transition state docking: a probe for noncovalent catalysis in biological systems. Application to antibody-catalyzed ester hydrolysis.
    Tantillo DJ; Houk KN
    J Comput Chem; 2002 Jan; 23(1):84-95. PubMed ID: 11913392
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Catalytic antibodies induced by a zwitterionic hapten.
    Tsumuraya T; Takazawa N; Tsunakawa A; Fleck R; Masamune S
    Chemistry; 2001 Sep; 7(17):3748-55. PubMed ID: 11575776
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Natural catalytic antibodies.
    Paul S
    Mol Biotechnol; 1996 Jun; 5(3):197-207. PubMed ID: 8837026
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Crystal structure of the complex of a catalytic antibody Fab fragment with a transition state analog: structural similarities in esterase-like catalytic antibodies.
    Charbonnier JB; Carpenter E; Gigant B; Golinelli-Pimpaneau B; Eshhar Z; Green BS; Knossow M
    Proc Natl Acad Sci U S A; 1995 Dec; 92(25):11721-5. PubMed ID: 8524836
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lysozyme-catalysed hydrolysis of some beta-aryl di-N-acetylchitobiosides.
    Lowe G; Sheppard G; Sinnott ML; Williams A
    Biochem J; 1967 Sep; 104(3):893-9. PubMed ID: 6049930
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fidelity in Hapten Design: How Analogous Are Phosphonate Haptens to the Transition States for Alkaline Hydrolyses of Aryl Esters?
    Tantillo DJ; Houk KN
    J Org Chem; 1999 Apr; 64(9):3066-3076. PubMed ID: 11674403
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An approach to sequence-specific antibody proteases. The use of haptens mimicking both a transition state and a distorted ground state.
    Smith RM; Yuan P; Weiner DP; Dutton CR; Hansen DE
    Appl Biochem Biotechnol; 1994; 47(2-3):329-42; discussion 342-3. PubMed ID: 7944347
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Aspects of antibody-catalyzed primary amide hydrolysis.
    Titmas RC; Angeles TS; Sugasawara R; Aman N; Darsley MJ; Blackburn G; Martin MT
    Appl Biochem Biotechnol; 1994; 47(2-3):277-90; discussion 291-2. PubMed ID: 7944343
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Crossreactivity, efficiency and catalytic specificity of an esterase-like antibody.
    Gigant B; Charbonnier JB; Eshhar Z; Green BS; Knossow M
    J Mol Biol; 1998 Dec; 284(3):741-50. PubMed ID: 9826512
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Toward selective covalent inactivation of pathogenic antibodies: a phosphate diester analog of vasoactive intestinal peptide that inactivates catalytic autoantibodies.
    Nishiyama Y; Bhatia G; Bangale Y; Planque S; Mitsuda Y; Taguchi H; Karle S; Paul S
    J Biol Chem; 2004 Feb; 279(9):7877-83. PubMed ID: 14676184
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Analysis of hapten binding and catalytic determinants in a family of catalytic antibodies.
    Ulrich HD; Schultz PG
    J Mol Biol; 1998 Jan; 275(1):95-111. PubMed ID: 9451442
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Investigation of a general base mechanism for ester hydrolysis in C-C hydrolase enzymes of the alpha/beta-hydrolase superfamily: a novel mechanism for the serine catalytic triad.
    Li JJ; Bugg TD
    Org Biomol Chem; 2007 Feb; 5(3):507-13. PubMed ID: 17252134
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Structural basis for a disfavored elimination reaction in catalytic antibody 1D4.
    Larsen NA; Heine A; Crane L; Cravatt BF; Lerner RA; Wilson IA
    J Mol Biol; 2001 Nov; 314(1):93-102. PubMed ID: 11724535
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Polyclonal catalytic antibodies.
    Ostler EL; Resmini M; Brocklehurst K; Gallacher G
    J Immunol Methods; 2002 Nov; 269(1-2):111-24. PubMed ID: 12379356
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Detection strategies for catalytic antibodies.
    Reymond JL
    J Immunol Methods; 2002 Nov; 269(1-2):125-31. PubMed ID: 12379357
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mechanism of an antibody-catalysed allylic isomerization.
    Gonçalves O; Dintinger T; Lebreton J; Blanchard D; Tellier C
    Biochem J; 2000 Mar; 346 Pt 3(Pt 3):691-8. PubMed ID: 10698695
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Completing the circle.
    Schultz PG; Lerner RA
    Nature; 2002 Aug; 418(6897):485. PubMed ID: 12152057
    [No Abstract]   [Full Text] [Related]  

  • 59. Origins and predictions of stereoselective antibody catalysis: theoretical analysis of Diels-Alder catalysis by 39A11 and its germ-line antibody.
    Zhang X; Deng Q; Yoo SH; Houk KN
    J Org Chem; 2002 Dec; 67(25):9043-53. PubMed ID: 12467427
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A general kinetic approach to investigation of active-site availability in macromolecular catalysts.
    Resmini M; Gul S; Carter S; Sonkaria S; Topham CM; Gallacher G; Brocklehurst K
    Biochem J; 2000 Feb; 346 Pt 1(Pt 1):117-25. PubMed ID: 10657247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.